GlaxoSmithKline plc ADR

GlaxoSmithKline is a pharmaceutical specialist that researches, develops, and manufactures pharmaceutics, vaccines, and non-prescription medicines. The company, which operates internationally, has its head office in Brentford, London, UK and was originally founded in 1715. GlaxoSmithKline has production and research and development facilities in more than 30 countries. These countries include the US, UK, Belgium, China, and Spain. As a publicly-listed company, GlaxoSmithKline stock trades on the NYSE with the ticker GSK. In December 2020, this company entered into a collaboration and licensing agreement with Icagen, a subsidiary of Ligand Pharmaceuticals Incorporated. The purpose of the agreement is to further research into small molecule therapeutics, for the treatment of neurological disorders. As of January 2021, GlaxoSmithKline proceeded with clinical studies on a second coronavirus treatment initiative, in partnership with Vir Biotechnology Incorporated. The company’s operations are divided into four segments – Pharmaceuticals, Pharmaceuticals R & D, Vaccines, and Consumer Healthcare. These segments develop and produce therapeutics such as respiratory, HIV, metabolic, and cardiovascular medicines. It also provides general healthcare essentials such as nutritional supplements, nasal sprays, gels, and toothpaste. GlaxoSmithKline is distinguished by its diverse offerings in the healthcare sector. Add this instrument to your eToro watchlist to receive news and updates on GSK share price developments.